Hackensack Meridian John Theurer Cancer Center is expanding its services, including acute leukemia and adult bone marrow stem cell transplantation, to Jersey Shore University Medical Center in Neptune City.
The Shore facility started offering John Theurer’s services on April 11, including access to more than 800 clinical trials and to research from a National Cancer Institute consortium.
JTCC at Hackensack University Medical Center is ranked as New Jersey’s best cancer center in by U.S. News & World Report and has a nationally recognized programs for blood cancers including multiple myeloma, lymphoma and leukemia, and one of the largest bone marrow transplant programs nationwide.
Making the services and research available at the Hope Tower in JSUMC increases access to care for patients in central and south Jersey.
“A patient who required a bone marrow transplant right now, they might be going up to Hackensack University Medical Center, they might be going out of state for those treatments—they’ll be able to receive them at JSUMC, which will be a huge convenience,” said Hackensack Meridian Health CEO Robert Garrett.
Both institutions have large oncology programs. John Theurer alone has treated approximately 63,000 patients in the past year, and since 1990 Hackensack University Medical Center, the location of its main campus, has done 7,500 bone marrow transplants.
With this expansion of services, JSUMC will also be one of the few sites offering CAR-T cell therapy in lymphoma, leukemia and myeloma, which Garrett called “the biggest breakthrough in cancer treatment in a generation.” John Theurer has been involved in CAR-T cell therapies, a personalized immunotherapy for certain blood cancers, for nearly a decade.
“Given the rapid acceleration in cancer, this could not be a better time to bring the benefit of innovation closer to patients’ homes. Having our experts rotate at JSUMC in the Hope Tower, will bring expertise, access to trials or cell therapy, when needed across our communities in Southern New Jersey, Pennsylvania and Delaware,” said Dr. Andre Goy, HMH’s physician-in-chief in oncology and JTCC chairman. “Together, partnering locally with our colleagues’ oncologists, we will expand access to tertiary and quaternary care and improve our patients’ outcome across the state of New Jersey.”
Two years of planning and coordination have gone into this expansion, Garrett told NJBIZ.
“This is a game changer for cancer treatment for this entire region,” he said. “I think it’s a big milestone for [John Theurer], really big for [JSUMC], but most importantly, the patients in central and southern New Jersey will benefit the most from this announcement,” he said. “There’s more and more population moving to Monmouth County and Ocean County and it’s something that’s absolutely needed in this area. Down in this part of the state there’s a pretty substantial senior population as well and they need this type of care closer to home.”